Authorization

GoodRx is going public. Here are the investors and executives that stand to make the most upon its debut.

GoodRx is going public. Here are the investors and executives that stand to make the most upon its debut.

GoodRx CEOs Doug Hirsch and Trevor Bezdek.
GoodRx



The prescription-discount startup GoodRx is expected to go public Wednesday at $33 per share, Axios and Reuters reported Tuesday.



In its initial S-1 filing, GoodRx disclosed that it has a dual-class stock structure that gives voting rights to some stockholders and not others.



However, the classes of stock will be worth about the same dollar amount upon the startup's public debut.



Here are the investors that stand to make the most money once GoodRx goes public.



Click here for more BI Prime stories.

GoodRx, the prescription-discount startup that recently started dabbling in digital health, is expected to go public on Wednesday.According to reports by Axios and Reuters, the startup priced shares at $33 on Tuesday ahead of Wednesday's expected debut, a price that's well above the $24 to $28 set range in an amended filing. Tuesday's set price would give GoodRx a market cap of around $12.7 billion. It will trade on the Nasdaq under the ticker GDRX. The debut will provide a windfall to investors and executives that have a significant stake in the company.Founded in 2011, GoodRx got its start as a place patients went to find coupons to make their prescriptions cheaper. It's since expanded to offer telemedicine services as well.
See also:
Leave a comment
News
  • Latest
  • Read
  • Commented
Calendar Content
«    Октябрь 2020    »
ПнВтСрЧтПтСбВс
 1234
567891011
12131415161718
19202122232425
262728293031